Distribution of a COVID Vaccine: Whose Interests Take Priority?

by: David Canter

Publication Date: January 11, 2021
Length: 5 pages
Product ID#: 5-975-263

Core Disciplines: Economics, Social Impact, Strategy & Management

Partner Collection:

Available Documents

Click on any button below to view the available document.

Don't see the document you need? Don't See the Document You Need?
Make sure you are registered and/or logged in to our site to view product documents. Once registered & approved, faculty, staff, & course aggregators will have access to full inspection copies and teaching notes for any of our materials.


Need to make copies?

If you need to make copies, you MUST purchase the corresponding number of permissions, and you must own a single copy of the product.

Electronic Downloads are available immediately after purchase. "Quantity" reflects the number of copies you intend to use. Unauthorized distribution of these files is prohibited pursuant to term of use of this website.

Teaching Note

This product has a teaching note available. Available only to Registered Educators. Please login to view it.


Late in 2020, ImmunVX, a fictional, multinational vaccine company, was among the leaders in developing a vaccine against the COVID-19 virus. It had accepted several government grants to help with the costs of developing the vaccine more rapidly. The company had a limited in-house manufacturing capacity yet had accepted orders from multiple governments that far exceeded its ability to meet those orders for at least the next three years. The company could increase its output by using contract manufacturing and/or by partnering with another large pharma company, though each option lowered the per-unit profit margin.

ImmunVX was proud of its relationships with high-, middle-, and low-income countries and accepted the variable profit margins from  these different markets. However, it had taken on significant debt in recent years due to acquisitions and R&D costs. As a consequence, it had incentivized its employees to focus on improved profit margins to repay those debts and improve the equity value to satisfy shareholders.

The challenge of this case lies in the discussion of a strategy that reconciles the needs of different stakeholders. An attempt to prioritize stakeholders in a simplistic way illustrates the weakness of thinking in terms of “or” rather than “and”. Thinking about “and” reframes the discussion to accept a decrease in short-term profit that might lead to longer-term gains. The case lends itself to a higher-level analysis using the PESTEL (Political, Economic, Social, Technological, Ethical and Legal) framework to identify macro-environmental factors that help guide a decision.

Teaching Objectives

After reading and discussing the material, students should:

  • Analyze a complex case in which there are conflicting priorities among the stakeholders.
  • Review the PESTEL analysis method and identify the key factors influencing the decision to allocate limited supplies of a vaccine.
  • Construct an overall plan for manufacturing and distribution that provides the greatest benefit to all stakeholders.